US Edition
News from curetoday.com
We’ve assigned a media bias rating of unknown to curetoday.com. You can read more about our methodology here.
Media Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top curetoday.com News
Breast Cancer · United StatesTUESDAY, Sept. 30, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Inluriyo (imlunestrant), an oral estrogen receptor antagonist, for the treatment of adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic…See the Story
FDA Approves Inluriyo for Advanced Breast Cancer
45% Center coverage: 18 sources
Breast Cancer · United StatesOn Thursday, the U.S. Food and Drug Administration (FDA) approved Eli Lilly and Co.’s (NYSE: LLY) Inluriyo (imlunestrant) for adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), ESR1-mutated advanced or metastatic breast cancer (MBC) whose disease progressed after at least one line of endocrine therapy (ET). The FDA approval is based on the results of the EMBER-3 trial in the patient populatio…See the Story
FDA Approves Eli Lilly's Drug For Advanced Breast Cancer - Eli Lilly (NYSE:LLY)
60% Center coverage: 5 sources
